-22.777777777777786," BRIEF-Lannett Anticipates Biosimilar Application For Insulin Glargine To Be Submitted By 2022 End June 11 (Reuters) - Lannett Company Inc: * LANNETT PROVIDES UPDATE ON CLINICAL ADVANCEMENT OF BIOSIMILAR INSULIN GLARGINE, FOLLOWING FDA MEETING * LANNETT COMPANY INC - ANTICIPATES BIOSIMILAR APPLICATION FOR INSULIN GLARGINE TO BE SUBMITTED BY END OF CALENDAR YEAR 2022 * LANNETT - FDA PROVIDED POSITIVE FEEDBACK ON CLINICAL AND CMC ADVANCEMENT OF BIOSIMILAR INSULIN GLARGINE THAT WAS CONSISTENT WITH CO’S EXPECTATIONS Source text for Eikon: Further company coverage:"
-35.12658227848101," BRIEF-Lannett Posts Q3 Loss Per Share Of $0.43 May 6 (Reuters) - Lannett Company Inc: * LANNETT ANNOUNCES FISCAL 2020 THIRD-QUARTER FINANCIAL RESULTS * Q3 SALES $144.4 MILLION VERSUS REFINITIV IBES ESTIMATE OF $134.5 MILLION * Q3 EARNINGS PER SHARE ESTIMATE $0.29 -- REFINITIV IBES DATA * SEES FY NET SALES $535 MILLION TO $545 MILLION, FROM $530 MILLION TO $550 MILLION * SEES FY ASSET IMPAIRMENT CHARGES $16 MILLION, UP FROM $2 MILLION * SEES FY CAPEX $15 MILLION TO $20 MILLION, DOWN FROM $20 MILLION TO $25 MILLION Source text for Eikon: Further company coverage:"
-12.824010914051847," BRIEF-Lannett To Meet With FDA Regarding The Clinical Advancement Of Biosimilar Insulin Glargine On June 9 April 8 (Reuters) - Lannett Company Inc: * LANNETT TO MEET WITH FDA REGARDING THE CLINICAL ADVANCEMENT OF BIOSIMILAR INSULIN GLARGINE ON JUNE 9 * LANNETT - EXPECT DISCUSSION WITH FDA TO INCLUDE DESIGN,ENDPOINT OF ANY ADDITIONAL HUMAN STUDIES REQUIRED FOR FILING BLA * LANNETT - EXPECT DISCUSSION WITH FDA TO INCLUDE APPROVAL OF INSULIN GLARGINE AS A BIOSIMILAR Source text for Eikon: Further company coverage:"
4.460431654676253, BRIEF-Lannett Begins Marketing Generic Adderall Xr March 31 (Reuters) - Lannett Company Inc: * LANNETT BEGINS MARKETING GENERIC ADDERALL® XR Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
-66.56891299524416," BRIEF-Lannett Receives FDA Approval For Dronabinol Capsules May 21 (Reuters) - Lannett Company Inc: * LANNETT COMPANY INC - RECEIVED APPROVAL OF ABBREVIATED NEW DRUG APPLICATION FOR DRONABINOL CAPSULES USP, 2.5 MG, 5 MG AND 10 MG * LANNETT - EXPECT TO COMMENCE MARKETING SEVERAL PRODUCTS INCLUDING DRONABINOL CAPSULES OVER COURSE OF YEAR * LANNETT COMPANY INC - FDA APPROVAL FOR DRONABINOL CAPSULES,THERAPEUTIC EQUIVALENT TO REFERENCE LISTED DRUG, MARINOL CAPSULES OF ABBVIE Source text for Eikon: Further company coverage:"
-11.858974358974358," BRIEF-Lannett Reports Q3 Adjusted Earnings Per Share $0.80 May 7 (Reuters) - Lannett Company Inc: * LANNETT ANNOUNCES FISCAL 2018 THIRD-QUARTER FINANCIAL RESULTS * Q3 SALES $174.4 MILLION VERSUS I/B/E/S VIEW $176.3 MILLION * Q3 EARNINGS PER SHARE VIEW $0.79 -- THOMSON REUTERS I/B/E/S * SEES FY 2018 GAAP NET SALES OF $685 MILLION TO $695 MILLION * SEES FY 2018 ADJUSTED NET SALES OF $685 MILLION TO $695 MILLION * LANNETT COMPANY SEES FY 2018 ADJUSTED GROSS MARGIN OF APPROXIMATELY 48% * Q3 EARNINGS PER SHARE VIEW $0.79, REVENUE VIEW $176.3 MILLION -- THOMSON REUTERS I/B/E/S * FY2018 REVENUE VIEW $687.3 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:"
-11.858974358974358," BRIEF-Lannett Acquires Portfolio Of Generic Products From Endo International May 7 (Reuters) - Lannett Company Inc: * LANNETT ACQUIRES PORTFOLIO OF GENERIC PRODUCTS FROM ENDO INTERNATIONAL * LANNETT COMPANY INC - TRANSACTION INCLUDES 23 APPROVED AND 1 PENDING DRUG PRODUCT APPLICATIONS, PRIMARILY ORAL SOLUTIONS * LANNETT - ACQUIRED 23 APPROVED AND ONE PENDING DRUG PRODUCT APPLICATIONS FROM UNIT OF ENDO FOR UPFRONT PAYMENT PLUS FUTURE MILESTONE PAYMENTS * LANNETT - EXPECT TO BEGIN LAUNCHING PRODUCTS, AFTER TRANSFER ACTIVITIES ARE COMPLETED, REGULATORY FILINGS MADE, ESTIMATED TO BE IN H2 2019 Source text for Eikon: Further company coverage:"
-21.7948717948718," BRIEF-Lannett Appoints Patrick Lepore Chairman Of Board April 30 (Reuters) - Lannett Company Inc: * LEPORE WILL SUCCEED JEFFREY FARBER, WHO WILL REMAIN A MEMBER OF BOARD Source text for Eikon: Further company coverage:"
